Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Rizzo

Psychiatry Clearwater, FL Doctor of Osteopathy

NPI 1508392820 CMS profile 5704005

28465 US Highway 19 N Ste 200, Clearwater, FL 33761

Open in the dashboard

General payments

$5,663

220 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Rizzo of Clearwater, FL is reported in the CMS Open Payments database as having received $5,663 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $881 37
2024 General $779 33
2023 General $1,576 68
2022 General $1,395 55
2021 General $1,031 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Rizzo
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Katherine Rizzo were reported at $881. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Katherine Rizzo Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $1,031 $143 $43–$576 $132
2022 $1,395 $153 $50–$590 $149
2023 $1,576 $170 $56–$651 $160
2024 $779 $179 $57–$673 $164
2025 $881 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $687 40 payments
  2. ITI, Inc. $686 27 payments
  3. Neuronetics, Inc. $627 12 payments
  4. Teva Pharmaceuticals USA, Inc. $447 16 payments
  5. Neurocrine Biosciences, Inc. $430 13 payments
  6. Otsuka America Pharmaceutical, Inc. $396 15 payments
  7. Alkermes, Inc. $362 17 payments
  8. Vanda Pharmaceuticals Inc. $347 11 payments
  9. Axsome Therapeutics, Inc. $338 10 payments
  10. Janssen Pharmaceuticals, Inc $314 15 payments
  11. Other $1,028 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,616 219 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $595 36 payments
  2. CAPLYTA $529 21 payments
  3. REXULTI $421 16 payments
  4. FANAPT $347 11 payments
  5. NEUROSTAR TMS THERAPY $342 3 payments
  6. Auvelity $338 10 payments
  7. HETLIOZ $319 10 payments
  8. INGREZZA $316 8 payments
  9. SPRAVATO $314 15 payments
  10. LYBALVI $275 13 payments
  11. Other $3,383 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

126

Median for Psychiatry & Neurology: 100

Drug cost

$1,820

Median for Psychiatry & Neurology: $2,986

Branded share of claims

16.7%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 21 $453
Clonazepam Generic 27 $380
Mirtazapine Generic 11 $308
Buprenorphine Hcl Generic 14 $217
Buspirone Hcl Generic 17 $212
Diazepam Generic 11 $89
Nortriptyline Hcl Generic 11 $88
Risperidone Generic 14 $75

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $135
$135 — —
REXULTI
  • Lundbeck LLC $55
  • Otsuka America Pharmaceutical, Inc. $47
$102 — —
Auvelity
  • Axsome Therapeutics, Inc. $89
$89 — —
SUBLOCADE
  • Indivior Inc. $83
$83 — —
CAPLYTA
  • ITI, Inc. $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record